CD274 and neoplasm: Programmed death 1 (PD-1) inhibitors offer a novel therapeutic approach by counteracting tumor-induced T-cell inhibition through blockade of the PD-1/programmed death ligand 1 or 2 (PD-L1/PD-L2) pathway.